Phase 3
Completed N=380
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Hematopoietic/Lymphoid Cancer · Nausea and vomiting · Unspecified Adult Solid Tumor, Protocol Specific
Source: ClinicalTrials.gov NCT02116530 ↗
Enrolled (actual)
380
Serious AEs
0.8%
Results posted
Apr 2017
Primary outcomePrimary: Proportion of Patients With no Nausea — 73.8; 45.3; 42.4; 25.4 percentage of participants
◆ Published Evidence
Highly cited
450citations · ~45 / year
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Summary
This randomized phase III trial studies antiemetic therapy with olanzapine to see how well they work compared to antiemetic therapy alone in preventing chemotherapy-induced nausea and vomiting in patients with cancer receiving highly emetogenic (causes vomiting) chemotherapy. Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients treated with chemotherapy. Olanzapine may help prevent chemotherapy-induced nausea and vomiting by blocking brain receptors that appear to be involved in nausea and vomiting.
Linked Publications
-
Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients With no Nausea |
73.8; 45.3; 42.4; 25.4; 37.3; 21.9 | — |
| SECONDARY Median Nausea Scores |
0; 0; 0; 1; 0; 1 | — |
| SECONDARY Proportion of Patients With Complete Response |
85.7; 64.6; 66.9; 52.4; 63.6; 40.6 | — |
| SECONDARY Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire |
0.4; 0.5; 2.3; 1.2; 1.6; 1.4 | — |
| SECONDARY Frequency of Rescue Medication |
156; 117; 21; 35; 3; 19 | — |
Eligibility Criteria
- Diagnosis of malignant disease
- No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide [AC])
- Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR
- Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
- Required Initial Laboratory Values ≤ 120 days prior to registration
- Serum Creatinine ≤2.0 mg/dL
- Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)
- Absolute neutrophil count (ANC) ≥1500/mm^3
- No nausea or vomiting ≤ 24 hours prior to registration
- Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)
- No severe cognitive compromise
- No known history of CNS disease (e.g. brain metastases, seizure disorder)
- No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy
- No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)
- No concurrent use of amifostine
- No concurrent abdominal radiotherapy
- No concurrent use of quinolone antibiotic therapy
- No chronic alcoholism (as determined by the investigator)
- No known hypersensitivity to olanzapine
- No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.
- No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)
Data sourced from ClinicalTrials.gov (NCT02116530) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.